Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment.

Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab (2014) 0.89

Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I. PLoS One (2016) 0.80

Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI. Mol Genet Metab (2016) 0.79

Pentosan Polysulfate: Oral Versus Subcutaneous Injection in Mucopolysaccharidosis Type I Dogs. PLoS One (2016) 0.78

Pathogenesis and treatment of spine disease in the mucopolysaccharidoses. Mol Genet Metab (2016) 0.75

The effect of Tlr4 and/or C3 deficiency and of neonatal gene therapy on skeletal disease in mucopolysaccharidosis VII mice. Mol Genet Metab (2014) 0.75

Treatment with pentosan polysulphate in patients with MPS I: results from an open label, randomized, monocentric phase II study. J Inherit Metab Dis (2016) 0.75

Dose translation from animal to human studies revisited. FASEB J (2007) 15.67

Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73

AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol (2011) 3.00

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics (2009) 2.44

Overview of the mucopolysaccharidoses. Rheumatology (Oxford) (2011) 1.64

Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res (2005) 1.51

Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis (2007) 1.47

Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum (2012) 1.42

Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A (2009) 1.37

Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) (2011) 1.24

Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest (2001) 1.18

Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) (2011) 1.18

S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4: implications for bone destruction in murine antigen-induced arthritis. Arthritis Rheum (2011) 1.08

Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol (2010) 1.07

Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One (2013) 1.06

Mucopolysaccharidosis type VI in rats: isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, and identification of the mutation. Genomics (1995) 1.01

Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther (2014) 1.01

The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum (1999) 0.97

Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI. J Clin Densitom (2013) 0.95

Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome. Int Urogynecol J (2010) 0.95

Evaluation of disease severity in mucopolysaccharidoses. J Pediatr Rehabil Med (2010) 0.93

Drug prevention of postoperative deep vein thrombosis. A compararative study of calcium heparinate and sodium pentosan polysulfate. Arch Surg (1976) 0.92

Enzyme replacement therapy for lysosomal storage diseases. Pediatr Endocrinol Rev (2012) 0.90

Mucopolysaccharidoses and other lysosomal storage diseases. Rheum Dis Clin North Am (2013) 0.90

Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity. J Inherit Metab Dis (2013) 0.89

Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients. Pediatr Res (2013) 0.87

Current and emerging management options for patients with Morquio A syndrome. Ther Clin Risk Manag (2013) 0.87

Postmortem findings in a case of variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulfate. J Neurol Neurosurg Psychiatry (2014) 0.85

Effects of intra-articular sodium pentosan polysulfate and glucosamine on the cytology, total protein concentration and viscosity of synovial fluid in horses. Aust Vet J (2012) 0.83

Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure. Orphanet J Rare Dis (2013) 0.83

Levels of chemerin and interleukin 8 in the synovial fluid of patients with inflammatory arthritides and osteoarthritis. Clin Exp Rheumatol (2014) 0.81

Evaluation of intramuscularly administered sodium pentosan polysulfate for treatment of experimentally induced osteoarthritis in horses. Am J Vet Res (2012) 0.80

Absolute and relative growth of the rat craniofacial skeleton. Arch Oral Biol (2004) 0.79

Combined Enzyme Replacement Therapy and Hematopoietic Stem Cell Transplantation in Mucopolysacharidosis Type VI. JIMD Rep (2011) 0.78

Antithrombotic therapy in patients with known risk factors for thromboembolism. Folia Haematol Int Mag Klin Morphol Blutforsch (1989) 0.77